Filing summary
Issuer identity: The supplied filing is TenX Keane Acquisition’s Form 10-Q for the quarter ended March 31, 2023. It does not appear to be a filing by Citius Oncology, Inc.; verify the issuer before relying on this summary.
Business context and reporting period
TenX Keane is a Cayman Islands SPAC formed to pursue a business combination. It had not begun operating activities and reported no operating revenue. The company completed its IPO in October 2022 and held most proceeds in a trust. This summary covers the three months ended March 31, 2023, compared with the same period in 2022.
Financial results and position
- Net income: $611,725, versus zero in Q1 2022. Interest income on trust investments was $759,647; general and administrative costs were $147,922.
- Revenue and margins: No operating revenue; operating loss was $147,922. Operating margins are not meaningful for this pre-combination SPAC.
- Cash flow: $168,799 used in operating activities; cash declined from $289,175 at year-end 2022 to $120,376 at March 31, 2023.
- Liquidity: Trust investments were $68.57 million, up from $67.81 million at December 31, 2022. The trust is primarily reserved for a business combination or shareholder redemptions and is distinct from cash available for operating expenses.
- Debt and liabilities: No long-term debt was reported. Current liabilities were $47,780, consisting of accrued formation costs.
- Equity: Shareholders’ equity was $197,586; 6.6 million public shares, with redemption rights, were classified outside permanent equity at $68.57 million.
Material changes versus the prior comparable period
Q1 2023 included trust investment income and operating expenses, producing net income of $611,725; the company reported no income or expenses in Q1 2022. Cash outside the trust fell by $168,799 during the quarter. Trust assets increased by approximately $760,000, reflecting interest income and the related redemption-value remeasurement.
Outlook, risks, and unusual items
- The company had not completed a business combination and reported substantial doubt about its ability to continue as a going concern, because the combination period may expire within one year of the financial statements’ issuance. The filing says the initial period is nine months from the IPO closing, with an extension to 18 months if extended; verify the applicable deadline and extension status.
- Management expected ongoing public-company, diligence, and transaction costs. It anticipated using the $120,376 outside the trust for target-search and related expenses; sponsor or affiliate financing may be available but is not assured.
- A subsequent-event note discloses an April 14, 2023 sponsor promissory note allowing borrowing up to $300,000, non-interest-bearing and due by April 14, 2024 or earlier upon a business combination or liquidation.
- Public shareholders may redeem shares in connection with a business combination or liquidation. If no combination is completed within the permitted period, the company must wind up and redeem public shares, subject to the filing’s terms.
- The company reported no material litigation, no long-term contractual obligations, and effective disclosure controls as of March 31, 2023. It stated it was not subject to market or interest-rate risk.
Important facts for investors to verify
- Whether this TenX Keane filing is relevant to the requested company, Citius Oncology.
- The business-combination deadline, whether an extension was exercised, and any later developments in the transaction search.
- Cash available outside the trust and the terms and availability of sponsor financing.
- The filing’s share-count and earnings-per-share allocations: some statement labels appear inconsistent with the share classifications elsewhere in the filing.
- The filing’s subsequent-event disclosure of the sponsor note alongside its statement that no subsequent events required disclosure.